Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4228945 | 0.89 | HRH3 (0.43) | PKMTAS1R3TAS1R1METMAPT | |
| SCHEMBL4226994 | 0.88 | PKM (0.46) | PKMTDP1ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL4231850 | 0.87 | PKM (0.48) | PKMTAS1R3TAS1R1MAPTRAB9A | |
| SCHEMBL4236665 | 0.86 | PKM (0.52) | PKMTDP1ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL4683259 | 0.86 | PKM (0.49) | PKMALDH1A1TAS1R3TAS1R1MAPT | |
| SCHEMBL4233255 | 0.85 | PKM (0.59) | PKMALDH1A1TAS1R3TAS1R1RAB9A | |
| SCHEMBL4784128 | 0.83 | EPHX1 (0.47) | TDP1ALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL4236662 | 0.82 | PKM (0.50) | PKMTDP1ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL4233270 | 0.82 | PKM (0.52) | PKMTDP1ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL4237924 | 0.82 | PKM (0.55) | PKMTDP1ALDH1A1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | claimed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | PKM 1734/4885TDP1 2128/4885ALDH1A1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.